Goswami B, Narang P, Mishra P S, Narang R, Narang U, Mendiratta D K
Department of Microbiology, Mahatma Gandhi Institute of Medical Sciences, Sevagram, Wardha, Maharashtra, India.
Department of Medicine, Mahatma Gandhi Institute of Medical Sciences, Sevagram, Wardha, Maharashtra, India.
Indian J Med Microbiol. 2016 Oct-Dec;34(4):442-447. doi: 10.4103/0255-0857.195375.
Non-tuberculous mycobacteria (NTM) are emerging as important pathogens. Their treatment also differs from that of Mycobacterium tuberculosis. In India, any datum on them is scarce as species identification and drug susceptibility are not performed in most laboratories. Susceptibility also differs from one geographic area to another, and in our country, there are no data even to guide the clinicians to start treatment empirically.
The present study endeavours to generate drug susceptibility data on NTM isolated from sputum samples collected and stored from 6445 symptomatics for pulmonary tuberculosis during a prevalence survey and from specimens received from the hospital. Isolates were not necessarily associated with the disease. Species were identified and antibiotic susceptibility was performed using micro-broth dilution technique as per the standard Clinical and Laboratory Standards Institute guidelines.
A total of 65 NTM with 11 species were identified, of which 27 belonged to Mycobacterium fortuitum complex, 14 Mycobacterium gordonae, 9 Mycobacterium avium, 7 Mycobacterium flavescens, 4 Mycobacterium scrofulaceum and one each of others. Sensitivity to amikacin for M. fortuitum was 95.22% (20 out of 21), followed by ciprofloxacin (76.19%) and clarithromycin (71.42%). All the 9 M. avium isolates, 11 of M. gordonae (78.57%), 5 of M. flavescens and 2 of M. scrofulaceum were sensitive to clarithromycin. All NTM were resistant to first-line antitubercular drugs except 8, which were sensitive to streptomycin.
Drug sensitivity of NTM varies from species to species. While amikacin was the best for rapidly growing mycobacteria, clarithromycin was the most active drug against M. avium and other slow growers.
非结核分枝杆菌(NTM)正逐渐成为重要的病原体。它们的治疗方法也与结核分枝杆菌不同。在印度,由于大多数实验室不进行菌种鉴定和药敏试验,关于它们的任何数据都很稀缺。药敏情况在不同地理区域也存在差异,在我国,甚至没有数据可指导临床医生进行经验性治疗。
本研究致力于生成从6445例肺结核症状患者在患病率调查期间收集并储存的痰液样本以及从医院接收的标本中分离出的NTM的药敏数据。分离株不一定与疾病相关。根据临床和实验室标准协会的标准指南,采用微量肉汤稀释技术进行菌种鉴定和抗生素药敏试验。
共鉴定出65株NTM,分属11个菌种,其中27株属于偶然分枝杆菌复合体,14株戈登分枝杆菌,9株鸟分枝杆菌,7株微黄分枝杆菌,4株瘰疬分枝杆菌,其他各1株。偶然分枝杆菌对阿米卡星的敏感性为95.22%(21株中的20株),其次是环丙沙星(76.19%)和克拉霉素(71.42%)。所有9株鸟分枝杆菌分离株、11株戈登分枝杆菌中的11株(78.57%)、5株微黄分枝杆菌和2株瘰疬分枝杆菌对克拉霉素敏感。除8株对链霉素敏感外,所有NTM对一线抗结核药物均耐药。
NTM的药敏情况因菌种而异。虽然阿米卡星对快速生长的分枝杆菌效果最佳,但克拉霉素是对抗鸟分枝杆菌和其他生长缓慢的分枝杆菌最有效的药物。